ONGLYZA® (saxagliptin)

How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?

SAVOR: The Onglyza CV outcomes study

SAVOR: Primary composite endpoint

The primary endpoint was a composite of cardiovascular death; myocardial infarction; or ischaemic stroke1

Primary Composite End-Point
Primary Composite End-Point

1. Scirica BM et al. N Engl J Med 2013; 369; 1317-1326.